FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) podcast

FDA D.I.S.C.O. Burst Edition: FDA approval of Welireg (belzutifan) for adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery

0:00
5:00
Rewind 15 seconds
Fast Forward 15 seconds
Listen to a soundcast of the August 8, 2021, FDA approval of Welireg (belzutifan) for patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery

More episodes from "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"

Get the whole world of podcasts with the free GetPodcast app.

Subscribe to your favorite podcasts, listen to episodes offline and get thrilling recommendations.

iOS buttonAndroid button